Jasper Therapeutics, Inc. (JSPR)Healthcare | Biotechnology | Redwood City, United States | NasdaqCM
1.06 USD
+0.04
(3.922%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:19 a.m. EDT
JSPR is a distressed biotech asset with no dividend, negative cash flow, and severe valuation fragmentation. While technicals show a temporary bounce back from multi-year lows, the forecasting model predicts a -6.5% move and options flow screams fear, positioning for further downside risk before any meaningful recovery. This is a high-risk speculative hold, not an investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.212850 |
| MSTL | 0.243952 |
| AutoARIMA | 0.245825 |
| AutoETS | 0.245884 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 21% |
| H-stat | 15.82 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 29.752 |
| Market Cap | 29,676,628 |
| Forward P/E | -0.63 |
| Beta | 3.20 |
| Website | https://jaspertx.com |
As of April 19, 2026, 12:19 a.m. EDT: Speculators are positioning for downside beta with heavy skews toward out-of-the-money (OTM) and deep out-of-the-money (DOTM) puts (strikes 2.5, 5.0, 7.5) despite the stock being under $1. Call activity is concentrated at strikes 2.5 and 5.0, functioning primarily as hedging protection rather than bullish speculation, with near-term call volume (April 17) being negligible. This imbalance indicates a 'cap' on the upside movement.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.75743705 |
| Address1 | 2,200 Bridge Pkwy |
| Address2 | Suite 102 |
| All Time High | 188.8 |
| All Time Low | 0.623 |
| Ask | 1.1 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 718,110 |
| Average Daily Volume3 Month | 499,440 |
| Average Volume | 499,440 |
| Average Volume10Days | 718,110 |
| Beta | 3.204 |
| Bid | 1.04 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 0.148 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.06 |
| Current Ratio | 2.625 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.12 |
| Day Low | 0.9614 |
| Debt To Equity | 29.752 |
| Display Name | Jasper Therapeutics |
| Earnings Timestamp | 1,774,900,800 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -80,527,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.028 |
| Enterprise Value | 2,219,628 |
| Eps Current Year | -2.44 |
| Eps Forward | -1.67 |
| Eps Trailing Twelve Months | -3.95 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.15492 |
| Fifty Day Average Change | -0.09492004 |
| Fifty Day Average Change Percent | -0.08218755 |
| Fifty Two Week Change Percent | -75.743706 |
| Fifty Two Week High | 7.19 |
| Fifty Two Week High Change | -6.13 |
| Fifty Two Week High Change Percent | -0.85257304 |
| Fifty Two Week Low | 0.623 |
| Fifty Two Week Low Change | 0.43699992 |
| Fifty Two Week Low Change Percent | 0.70144445 |
| Fifty Two Week Range | 0.623 - 7.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,578,666,600,000 |
| Float Shares | 21,879,514 |
| Forward Eps | -1.67 |
| Forward P E | -0.6347305 |
| Free Cashflow | -47,189,376 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 22 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01044 |
| Held Percent Institutions | 0.73203003 |
| Implied Shares Outstanding | 27,996,819 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,704,326,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California. |
| Long Name | Jasper Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 29,676,628 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_647336542 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -75,801,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 29,676,628 |
| Number Of Analyst Opinions | 5 |
| Open | 1.03 |
| Operating Cashflow | -77,161,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 650 549 1400 |
| Pre Market Change | -0.01999998 |
| Pre Market Change Percent | -1.8867908 |
| Pre Market Price | 1.04 |
| Pre Market Time | 1,776,773,846 |
| Previous Close | 1.02 |
| Price Eps Current Year | -0.4344262 |
| Price Hint | 4 |
| Price To Book | 7.162162 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.174 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.04 |
| Regular Market Change Percent | 3.92157 |
| Regular Market Day High | 1.12 |
| Regular Market Day Low | 0.9614 |
| Regular Market Day Range | 0.9614 - 1.12 |
| Regular Market Open | 1.03 |
| Regular Market Previous Close | 1.02 |
| Regular Market Price | 1.06 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 639,621 |
| Return On Assets | -0.88157 |
| Return On Equity | -2.3031101 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 27,996,819 |
| Shares Percent Shares Out | 0.107700005 |
| Shares Short | 3,015,156 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,340,380 |
| Short Name | Jasper Therapeutics, Inc. |
| Short Percent Of Float | 0.1084 |
| Short Ratio | 7.8 |
| Source Interval | 15 |
| State | CA |
| Symbol | JSPR |
| Target High Price | 20.0 |
| Target Low Price | 1.5 |
| Target Mean Price | 7.7 |
| Target Median Price | 6.0 |
| Total Cash | 28,692,000 |
| Total Cash Per Share | 1.025 |
| Total Debt | 1,235,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.95 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.028955 |
| Two Hundred Day Average Change | -0.96895504 |
| Two Hundred Day Average Change Percent | -0.4775636 |
| Type Disp | Equity |
| Volume | 639,621 |
| Website | https://jaspertx.com |
| Zip | 94,065 |